Prognostic Factors for HCC and Liver Transplantation in Patients With MASLD/MASH
Recruiting
Observational Study
Metabolic Dysfunction-Associated Steatotic Liver Disease
Hepatocellular Carcinoma
Metabolic Dysfunction-Associated Steatohepatitis
Liver Transplant
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Observational
- Participants needed
- 1,000 (estimated)
- Sponsor
- IRCCS Azienda Ospedaliero-Universitaria di Bologna · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The BOMASH study is a single-center, prospective/retrospective observational study without pharmacological interventions. It will include all patients diagnosed with Metabolic-Associated Steatotic Liver Disease (MASLD/MASH), whether newly diagnosed or previously identified at the center during follow-up or as part of routine diagnostic and therapeutic care.
The aim of the study is to identify pre…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* All patients with a diagnosis of MASLD, established according to the most recent published guidelines (EASL, EASD, EASO)
* Age ≥18 years
Inclusion Criteria for Biological Sample Collection:
* Patients requiring liver biopsy for diagnostic purposes, as indicated by the most r…
Contacts